KaloBios Pharmaceuticals Inc failed in a mid-stage study and put a pause to the development of its drug for lung infections in cystic fibrosis patients.
KB001-A, was the drug developed to delay worsening respiratory tract symptoms and reduce the extent of intake of antibiotics in patients with cystic fibrosis.
Cystic fibrosis also known as mucoviscidosis, is an autosomal recessive genetic disorder that affects mostly the lungs but also the pancreas, liver, and intestine.
Frequent lung infections cause a serious symptom of difficulty in breathing. Other symptoms including sinus infections, poor growth, and infertility affect other parts of the body.
An estimated 30,000 children are affected with Cystic fibrosis and occurs in the rate of 1 in 3400 births.
KB001-A was developed to treat lung infections caused by a powerful superbug, Pseudomonas aeruginosa.
The drug also failed to improve lung function, which was the trial's secondary endpoint.
Patients with cystic fibrosis are on antibiotics to reduce infection.
The data on the complete report of the drug's failure was not yet analysed by KaloBios.